Wearable Blood Pressure Monitoring in 2026: FDA Regulations, Samsung Launch, and the Future of Smartwatch Health Tracking

Key Takeaway: 2026 marks a watershed year for wearable blood pressure monitoring. The FDA has cleared wrist-watch BP monitors with clinical accuracy of 1.3 mmHg mean deviation, Samsung finally launched blood pressure tracking for US Galaxy Watch users (requiring monthly cuff calibration), and new FDA guidance distinguishes between regulated medical device features and general wellness software. These developments signal that wrist-based BP monitoring is transitioning from experimental to mainstream.

The State of Wearable Blood Pressure Monitoring in 2026

After years of development and regulatory hurdles, wearable blood pressure monitoring has reached a tipping point in 2026. Three major developments have converged to make wrist-based BP measurement a practical reality: the FDA cleared the first wrist-watch electronic BP monitor from Shenzhen Urion Technology in May 2026, Samsung finally brought blood pressure tracking to US Galaxy Watch users in March 2026, and the FDA updated its regulatory framework to clarify the distinction between medical devices and wellness products.

These developments open the door for smartwatch makers to offer BP-related features while maintaining appropriate regulatory oversight for clinical-grade measurements.

FDA Clearance: Wrist-Watch BP Monitor (May 2026)

On May 14, 2026, the FDA cleared Shenzhen Urion Technology’s Wrist Watch Electronic Blood Pressure Monitor (models U16H through U19T) via the 510(k) premarket notification process. This device uses the oscillometric method with an integrated airbag and cuff built into the watch strap, automatically inflating and deflating to measure systolic and diastolic blood pressure.

Clinical validation results are impressive: In a study of 103 subjects following ISO 81060-2:2018+AMD1:2020+AMD2:2024 standards, the device achieved a mean systolic deviation of 1.3 mmHg (SD 6.2 mmHg) and a mean diastolic deviation of -1.5 mmHg (SD 4.9 mmHg). These results comfortably exceed the acceptance criteria of mean deviation within 5.0 mmHg and standard deviation within 8.0 mmHg.

The device is intended for adults with wrist circumference between 15-21 cm who do not have arrhythmias like atrial fibrillation and are not pregnant. It includes irregular heartbeat detection and stores up to 200 measurement records depending on the model variant.

Samsung Brings BP Monitoring to US Users (March 2026)

After launching the feature in South Korea over six years ago, Samsung finally rolled out blood pressure tracking to US Galaxy Watch users in March 2026. The feature works on Galaxy Watch 4 and later models running Wear OS 4.0 or higher, paired with a Samsung Galaxy phone running Android 12 or later.

A critical limitation remains: the feature requires calibration using a traditional upper-arm blood pressure cuff every 28 days. Samsung has positioned this as a wellness feature rather than a regulated medical device, similar to how Whoop approached FDA compliance. The company has announced that passive monitoring to show BP trends over time will be added later in 2026.

FDA Regulatory Shift: Wellness vs Medical Devices (June 2026)

The FDA’s updated guidance on wearable regulation represents one of the most consequential shifts for the industry. Under the new framework, heart rate and ECG features can be treated as general wellness tools rather than tightly controlled medical devices, provided manufacturers present them as wellness insights rather than clinical diagnostic tools.

This distinction matters because it determines how quickly new features can reach consumers. An ECG algorithm that flags possible atrial fibrillation and directs users to contact a doctor remains a regulated medical device. A heart rate variability score that suggests better sleep habits is classified as low-risk digital health coaching, allowing faster deployment.

The practical impact is that the same sensor hardware can power both wellness features (unregulated, fast to market) and medical features (regulated, requires clinical validation) depending on how the software functions are described.

Three Technologies Compared

Oscillometric (cuff-based): The Urion device and many traditional home monitors use this method. An integrated airbag inflates at the wrist and measures pressure oscillations. This is the most validated approach but requires inflation hardware in the watch band.

Bio-impedance (BioZ): A breakthrough study published in Nature Communications (May 2026) demonstrated cuffless hemodynamic monitoring using a smartwatch with real-time electrical bioimpedance sensing. A physics-informed neural network incorporating fluid dynamics principles enables BP estimation without any cuff. This technology was successfully tested on healthy individuals, post-exercise subjects, and patients with hypertension in both outpatient and ICU settings.

Samsung’s PPG-based estimation: Uses the existing heart rate sensors to estimate BP after calibration with a traditional cuff. Convenient but requires periodic recalibration and cannot match the accuracy of oscillometric or BioZ methods.

What This Means for Consumers

When evaluating wearable BP devices in 2026, look for explicit FDA clearance language for specific features. Packaging that says “supports heart health” or “intended to support better wellness” without naming a disease condition likely indicates a wellness product under the updated guidance, not a clinically validated medical device.

For users with diagnosed hypertension or cardiovascular conditions, traditional BP cuffs remain the gold standard. Wearable BP monitors serve as supplementary tools for trend tracking between clinical measurements.

Frequently Asked Questions

Can I trust smartwatch blood pressure readings?

FDA-cleared devices like the Urion wrist monitor show clinical accuracy within 1.3 mmHg mean deviation, which meets ISO standards. However, wellness-focused features without FDA clearance may have lower accuracy. Always verify regulatory status.

Does the Samsung Galaxy Watch measure blood pressure accurately?

Galaxy Watch BP tracking requires monthly calibration with a traditional cuff and uses PPG sensors for estimation. It is positioned as a wellness feature, not a medical device. Accuracy depends on proper calibration.

Is cuffless blood pressure monitoring available in 2026?

Yes. Research published in Nature Communications (May 2026) demonstrated a cuffless BioZ-based approach using physics-informed machine learning, with successful testing on hypertensive patients. However, commercial availability is still emerging.

What changed with FDA regulations for wearables in 2026?

The FDA clarified the distinction between medical device features (clinical decision support, diagnosis) and wellness features (general health insights). This allows faster innovation for non-clinical features while maintaining rigorous review for medical claims.

Do I still need a traditional BP cuff?

For diagnosed hypertension, yes. Even the most advanced wearables like Samsung’s require monthly cuff calibration. Wearable BP monitoring is best used for trend tracking between traditional measurements.

Related Reading

• Edge AI in Industrial IoT 2026
• STM32 BME280 Environmental Monitoring Guide

Sources

• Wrist Watch Electronic BP Monitor FDA 510(k) – Innolitics
• Samsung BP Monitoring US Launch – Samsung Newsroom
• Samsung Galaxy Watch BP US Launch – The Verge
• Cuffless Hemodynamic Monitoring with ML – Nature Communications
• FDA Wearable Regulation 2026 Analysis

Disclosure: Some links in this article are affiliate links. We may earn a commission if you purchase through these links at no additional cost to you.